We have located links that may give you full text access.
The incidence of atrial fibrillation with trastuzumab treatment: A systematic review and meta-analysis.
Cardiovascular Therapeutics 2018 October 30
AIM: Cases of cardiotoxicity related to trastuzumab have been reported. This systematic review and meta-analysis evaluated the risk of atrial fibrillation (AF) in patients of breast cancer treated with trastuzumab.
METHODS: PubMed and EMBASE were searched until September 2017 for articles that investigated AF incidence in patients receiving trastuzumab for breast cancer.
RESULTS: A total of 15 studies involving 8124 patients treated with trastuzumab were included. Of the total cohort, 37 patients suffered from AF, giving rise to an incidence of 1.22% (95% confidence interval [CI]: 0.56%-2.68%). No significant difference in the incidence of AF was found between ado-trastuzumab emtansine (0.95%, 95% CI: 0.36%-2.52%) and trastuzumab groups (1.32%, 95% CI: 0.52%-3.34%), trastuzumab combined with other antineoplastic agents (2.09%, 95% CI: 1.16%-3.73%) and trastuzumab alone (0.36%, 95% CI: 0.04%-3.08%), prior exposure to anthracyclines (1.72%, 95% CI: 0.75%-3.88%) and no prior exposure (1.03%, 95% CI: 0.30%-3.51%), and radiotherapy (1.26%, 95% CI: 0.68%-2.33%) vs. no radiotherapy (1.21%, 95% CI: 0.35%-4.14%).
CONCLUSIONS: Atrial fibrillation incidence in breast cancer patients receiving trastuzumab was around 1.2%. It was not influenced by the formulation of trastuzumab, the additional use of neoplastic agents, anthracycline exposure status, or concurrent radiotherapy.
METHODS: PubMed and EMBASE were searched until September 2017 for articles that investigated AF incidence in patients receiving trastuzumab for breast cancer.
RESULTS: A total of 15 studies involving 8124 patients treated with trastuzumab were included. Of the total cohort, 37 patients suffered from AF, giving rise to an incidence of 1.22% (95% confidence interval [CI]: 0.56%-2.68%). No significant difference in the incidence of AF was found between ado-trastuzumab emtansine (0.95%, 95% CI: 0.36%-2.52%) and trastuzumab groups (1.32%, 95% CI: 0.52%-3.34%), trastuzumab combined with other antineoplastic agents (2.09%, 95% CI: 1.16%-3.73%) and trastuzumab alone (0.36%, 95% CI: 0.04%-3.08%), prior exposure to anthracyclines (1.72%, 95% CI: 0.75%-3.88%) and no prior exposure (1.03%, 95% CI: 0.30%-3.51%), and radiotherapy (1.26%, 95% CI: 0.68%-2.33%) vs. no radiotherapy (1.21%, 95% CI: 0.35%-4.14%).
CONCLUSIONS: Atrial fibrillation incidence in breast cancer patients receiving trastuzumab was around 1.2%. It was not influenced by the formulation of trastuzumab, the additional use of neoplastic agents, anthracycline exposure status, or concurrent radiotherapy.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app